Nasdaq
$41.75▲ 0.61%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.00BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.1After-hours26.10.02 05:19144Ownership#●●●#●●●
Scholar Rock Holding Corp
Insider Katie Peng of Scholar Rock Holding Corp has filed a Form 144 to report a proposed sale of 144 shares of the company's common stock. This filing serves as a formal notification of the insider's intent to dispose of these shares.…more
$41.75+0.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25After-hours26.09.26 05:124Ownership
Scholar Rock Holding Corp
Insider Keith Woods of Scholar Rock Holding Corp filed a Form 4 statement of changes in beneficial ownership of securities on September 24, 2026. This filing officially records the change in the executive's equity holdings.…more
$41.75+0.61%vs prev closeView filingShare - 9.23After-hours26.09.24 05:364Ownership
Scholar Rock Holding Corp
Insider David Hallal of Scholar Rock Holding Corp filed a Form 4 report regarding changes in beneficial ownership of securities as of September 21, 2026. This filing serves as an official disclosure of insider stock activity.…more
$41.75+0.61%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 21:56Bullish#●●●#●●●#●●●
Scholar Rock Receives FDA Priority Review Voucher for Isembyld
Scholar Rock has been granted an FDA priority review voucher for its rare pediatric disease treatment, Isembyld. This designation provides the company with a strategic advantage by potentially accelerating future drug review timelines.…more
$41.75+0.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Pre-market26.10.08 21:04
●●●●●●●● ●●●●● ●●●●●●
Scholar Rock has resubmitted its Marketing Authorization Application to the EMA for apitegromab to treat spinal muscular atrophy. This submission follows ongoing dialogue with European regulators, marking a key step in the drug's path to approval.…more
$41.75+0.61%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 22:24
●●●●●●●● ●●●●● ●●●●●●
Scholar Rock's ISEMBYLD has been approved by the FDA as the first muscle-targeted therapy for spinal muscular atrophy. The drug demonstrated significant improvements in motor function during Phase 3 trials and secured a Rare Pediatric Disease Priority Review Voucher.…more
$41.75+0.61%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report